T Cell Media: Why NB-ROC™ Outperforms Standard Media For CAR-T Cell Manufacturing

By Asma Ayari, Ph.D., director of research and development at Nucleus Biologics

T cells are the powerful foundation for cutting-edge immunotherapies, yet their full clinical potential hinges on the quality of their culture environment. Traditional proprietary T cell media often introduces significant challenges to CAR-T cell manufacturing due to a lack of transparency, lot-to-lot variability from serum, and complex regulatory hurdles associated with undefined or animal-derived components. These factors can introduce risk and inconsistency at every stage of development, directly impacting cell viability, transduction efficiency, and therapeutic potency.

Optimizing your T cell media is a critical decision in the CAR-T workflow. Learn how a serum-free and xeno-free formulation was designed to address these roadblocks. Benchmarking data shows how NB-ROC™ T Cell Serum-Free Medium outperforms a leading standard, demonstrating up to a 3-fold increase in viral transduction efficiency. This can lead to higher CAR expression, lower viral load requirements, and a more cost-effective manufacturing process.

Gain greater control over your cell therapy with a reproducible, high-performance solution that simplifies the transition from research to clinic. Discover the data and specifications of NB-ROC by downloading the full article.